Skip to content
OpenCapital
Get started

Aclaris Therapeutics ACRS D&A

D&A at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$17K-87.4%

Other financials

Income statement

See full
Revenue$2.0M+37.2%
Gross profit$1.6M+68.7%
Operating income-$22.2M-22.7%
Net income-$19.8M-31.4%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$28.7M-5.6%
Total debt$2.0M-20.1%
Total equity$143.6M-0.3%
Total assets$198.7M+0.3%

Cash flow

See full
Operating cash flow-$18.1M-39.0%
CapEx$13.0K-69.8%
Free cash flow-$18.2M-38.6%

Valuation

See full
Market cap$685.75M+337%
Enterprise value$659.07M+410%
P/S82×+73.1×

Profitability

See full
Gross margin76.3%-9.7pp
Operating margin-961.9%+259pp
Net margin-832.6%+132pp
FCF margin-624.9%—

Returns & leverage

See full
Return on equity-48.4%-15.4pp
Debt / equity0×0.0×
Current ratio4×-1.0×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aclaris Therapeutics's D&A?
Aclaris Therapeutics (ACRS) reported D&A of $102K in Q1 2026.
How has Aclaris Therapeutics's D&A changed year-over-year?
Aclaris Therapeutics's D&A decreased by 20.3% year-over-year, from $128K to $102K.
What is the long-term trend for Aclaris Therapeutics's D&A?
Over 4 years (2021 to 2025), Aclaris Therapeutics's D&A has grown at a -16.3% compound annual growth rate (CAGR), from $923K to $454K.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.